{"id":"mecamylamine-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mecamylamine competitively blocks nicotinic acetylcholine receptors at the ganglia of both the sympathetic and parasympathetic nervous systems. By inhibiting ganglionic transmission, it reduces sympathetic outflow and lowers blood pressure. It has been historically used as an antihypertensive agent and is being investigated for other conditions including smoking cessation and Tourette syndrome.","oneSentence":"Mecamylamine is a non-selective nicotinic acetylcholine receptor antagonist that blocks neural transmission in the autonomic nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:09.789Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (historical indication)"},{"name":"Smoking cessation (investigational)"},{"name":"Tourette syndrome (investigational)"}]},"trialDetails":[{"nctId":"NCT03914677","phase":"PHASE4","title":"Mecamylamine for Autonomic Dysreflexia Prophylaxis","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-06-13","conditions":"Spinal Cord Injuries","enrollment":5},{"nctId":"NCT01152554","phase":"PHASE3","title":"A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Major Depressive Disorder, MDD, Depression","enrollment":813},{"nctId":"NCT01153347","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Major Depressive Disorder, Depression","enrollment":2409},{"nctId":"NCT01157078","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Major Depressive Disorder, Depression","enrollment":319},{"nctId":"NCT01180400","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Major Depressive Disorder, Depression","enrollment":295},{"nctId":"NCT01240967","phase":"PHASE1","title":"To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Healthy Volunteers, Patients, Pharmacokinetics","enrollment":40},{"nctId":"NCT01288079","phase":"PHASE2","title":"A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2011-02","conditions":"Major Depressive Disorder","enrollment":145},{"nctId":"NCT01458899","phase":"PHASE1","title":"Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT01145768","phase":"PHASE1","title":"To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Healthy","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vecamyl"],"phase":"marketed","status":"active","brandName":"Mecamylamine Oral Tablet","genericName":"Mecamylamine Oral Tablet","companyName":"Wayne State University","companyId":"wayne-state-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mecamylamine is a non-selective nicotinic acetylcholine receptor antagonist that blocks neural transmission in the autonomic nervous system. Used for Hypertension (historical indication), Smoking cessation (investigational), Tourette syndrome (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}